Molecular basis of therapeutic approaches to gastric cancer

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 1, 2009, Pages 37-41

  Wu, Kaichun ^a   Nie, Yongzhan ^a   Guo, Changcun ^a   Chen, Yu ^a   Ding, Jie ^a   Fan, Daiming ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Angiopoietin; Cyclooxygenase 2; Gastric cancer; Growth receptor kinase; Immunotherapy; MG7 Ag; Osteopontin; Potassium channel; RUNX3

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; ANGIOPOIETIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; ANTINEOPLASTIC AGENT; CANCER VACCINE; CETUXIMAB; CYCLIC AMP; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DNA VACCINE; ERLOTINIB; IMATINIB; MG7 ANTIGEN; OSTEOPONTIN; POTASSIUM CHANNEL HERG; PROSTAGLANDIN E2; PROTEIN BCL 2; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR RUNX3; TRASTUZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER THERAPY; CARCINOGENESIS; CELL MEDIATED CYTOTOXICITY; CHRONIC MYELOID LEUKEMIA; CYTOTOXIC T LYMPHOCYTE; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL STROMAL TUMOR; GENE OVEREXPRESSION; HUMAN; IMMUNE RESPONSE; LUNG NON SMALL CELL CANCER; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; RNA INTERFERENCE; STOMACH CANCER; TUMOR SUPPRESSOR GENE;

EID: 58549096505     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05753.x     Document Type: Review

References (48)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005 55 : 74 108.
2. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide, IARC Cancer Base No. 5, version 2.0. Lyon : IARC Press, 2004.
3. Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 1996 2 : 561 6.
4. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2001 2 : 127 37.
5. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001 344 : 783 92.
6. O'Rourke DM, Kao GD, Singh N et al. Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells. Proc. Natl. Acad. Sci. USA 1998 95 : 10842 7.
7. Subbaramaiah K, Telang N, Ramonetti JT et al. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res. 1996 56 : 4424 9.
8. Sheehan KM, Sheahan K, O'Donoghue DP et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999 282 : 1254 7.
9. Sung JJ, Leung WK, Go MY et al. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am. J. Pathol. 2000 157 : 729 35.
10. Oshima M, Dinchuk JE, Kargman SL et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996 87 : 803 9.
11. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN. Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest. 2000 105 : 1589 94.
12. Liu CH, Chang SH, Narko K et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J. Biol. Chem. 2001 276 : 18563 9.
13. Hu PJ, Yu J, Zeng ZR et al. Chemoprevention of gastric cancer by celecoxib in rats. Gut 2004 53 : 195 200.
14. Wu H, Wu K, Yao L, Xu M, Fan D. Antisense inhibition of cyclooxygenase-2 reduces malignant phenotype of gastric cancer cells. Zhonghua Nei Ke Za Zhi 2002 41 : 534 7.
15. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 1998 58 : 409 12.
16. Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res. 1996 56 : 4566 9.
17. Fu YG, Sung JJ, Wu KC et al. Inhibition of gastric cancer-associated angiogenesis by antisense COX-2 transfectants. Cancer Lett. 2005 224 : 243 52.
18. Joo YE, Rew JS, Seo YH et al. Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer. J. Clin. Gastroenterol. 2003 37 : 28 33.
19. Uefuji K, Ichikura T, Mochizuki H. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin. Cancer Res. 2000 6 : 135 8.
20. Yu HG, Li JY, Yang YN et al. Increased abundance of cyclooxygenase-2 correlates with vascular endothelial growth factor-A abundance and tumor angiogenesis in gastric cancer. Cancer Lett. 2003 195 : 43 51.
21. Leung WK, To KF, Go MY et al. Cyclooxygenase-2 upregulates vascular endothelial growth factor expression and angiogenesis in human gastric carcinoma. Int. J. Oncol. 2003 23 : 1317 22.
22. Miller C. An overview of the potassium channel family. Genome Biol. 2000 1 : REVIEWS0004.
23. Smith GA, Tsui HW, Newell EW et al. Functional up-regulation of HERG K channels in neoplastic hematopoietic cells. J. Biol. Chem. 2002 277 : 18528 34.
24. Shao XD, Wu KC, Hao ZM, Hong L, Zhang J, Fan DM. The potent inhibitory effects of Cisapride, a specific blocker for human ether-a-go-go-related gene (HERG) channel, on gastric cancer cells. Cancer Biol. Ther. 2005 4 : 295 301.
25. Liu Z, Wang X, Lu Y et al. Expression of 15-PGDH is down-regulated by COX-2 in gastric cancer. Carcinogenesis 2008 29 : 1219 27.
26. Ding Y, Tong M, Liu S, Moscow JA, Tai HH. NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis 2005 26 : 65 72.
27. Tai HH, Cho H, Tong M, Ding Y. NAD+-linked 15-hydroxyprostaglandin dehydrogenase: structure and biological functions. Curr. Pharm. Des. 2006 12 : 955 62.
28. Swami S, Krishnan AV, Moreno J, Bhattacharyya RB, Peehl DM, Feldman D. Calcitriol and genistein actions to inhibit the prostaglandin pathway: potential combination therapy to treat prostate cancer. J. Nutr. 2007 137 (Suppl. 1 S205 10.
29. Moreno J, Krishnan AV, Swami S, Nonn L, Peehl DM, Feldman D. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res. 2005 65 : 7917 25.
30. Yan M, Rerko RM, Platzer P et al. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc. Natl. Acad. Sci. USA 2004 101 : 17468 73.
31. Li QL, Ito K, Sakakura C et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002 109 : 113 24.
32. Guo C, Ding J, Yao L et al. Tumor suppressor gene Runx3 sensitizes gastric cancer cells to chemotherapeutic drugs by down regulating Bcl-2,MDR-1 and MPR-1. Int. J. Cancer 2005 116 : 155 60.
33. Papetti M, Herman IM. Mechanisms of normal and tumor-derived angiogenesis. Am. J. Physiol. Cell Physiol. 2002 282 : C947 70
34. Shim WS, Teh M, Bapna A et al. Angiopoietin 1 promotes tumor angiogenesis and tumor vessel plasticity of human cervical cancer in mice. Exp. Cell Res. 2002 279 : 299 309.
35. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann. Surg. 1972 175 : 409 16.
36. Takagi H, Koyama S, Seike H et al. Potential role of the angiopoietin/Tie2 system in ischemia-induced retinal neovascularization. Invest. Ophthalmol. Vis. Sci. 2003 44 : 393 402.
37. Wang J, Wu K, Zhang D et al. Expressions and clinical significances of angiopoietin-1, -2 and Tie2 in human gastric cancer. Biochem. Biophys. Res. Commun. 2005 337 : 386 93.
38. Wang J, Wu KC, Zhang DX, Fan DM. Antisense angiopoietin-1 inhibits tumorigenesis and angiogenesis of gastric cancer. World J. Gastroenterol. 2006 12 : 2450 4.
39. Wang J, Wu K, Bai F et al. Celecoxib could reverse the hypoxia-induced angiopoietin-2 upregulation in gastric cancer. Cancer Lett. 2006 242 : 20 7.
40. Tang H, Wang J, Bai F et al. Positive correlation of osteopontin, cyclooxygenase-2 and vascular endothelial growth factor in gastric cancer. Cancer Invest. 2008 26 : 60 7.
41. Tang H, Wang J, Bai F et al. Inhibition of osteopontin would suppress angiogenesis in gastric cancer. Biochem. Cell. Biol. 2007 85 : 103 10.
42. Zhi M, Wu KC, Dong L et al. Characterization of a specific phage-displayed peptide binding to vasculature of human gastric cancer. Cancer Biol. Ther. 2004 3 : 1232 5.
43. Xu L, Qiao T, Chen B. Mimic epitope recognized by monoclonal antibody MG7 against gastric cancer through screening phage displayed random peptide library. Zhonghua Yi Xue Za Zhi 2000 80 : 304 7.
44. Xu L, Xu H, Ma F. Immunogenicity of phage-displayed tumor antigen-mimic peptide. Zhonghua Zhong Liu Za Zhi 2001 23 : 187 9.
45. Ning XX, Wu KC, Guo CC et al. Immunological Characterization of a DNA vaccine of gastric cancer-related MG7-Ag mimotope fused with heat shock protein 70. J. Tumor Marker Oncol. 2003 18 : 50 63.
46. Chen Y, Wu K, Guo C et al. A novel DNA vaccine containing four mimicry epitopes for gastric cancer. Cancer Biol. Ther. 2005 4 : 308 12.
47. Shi R, Hong L, Wu D et al. Enhanced immune response to gastric cancer specific antigen peptide by coencapsulation with CpG oligodeoxynucleotides in nanoemulsion. Cancer Biol. Ther. 2005 4 : 218 24.
48. Nie Y, Wu K, Yang J et al. Induction of T lymphocytes specific to human gastric cancer using HLA-A matched allogeneic gastric tumor cells. J. Immunother. 2003 26 : 403 11.